Drug Trial Radar · NCT00624338
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
Last checked: Nov 20, 2026Latest source record: Mar 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
461
Actual
Start
Jan 2008
Primary completion
Apr 2012
Study completion Oct 2012
Sponsor
- Lead sponsor
- EMD SeronoIndustry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- Feb 27, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the efficacy and safety of atacicept compared to placebo in preventing new flares in subjects with systemic lupus erythematosus (SLE) and to confirm the optimal dose of atacicept for treatment of subjects with SLE and gain information on the effect of atacicept on markers specific to its mechanism of action (MoA) and their correlation to disease activity/progression. Study medication will be administered through subcutaneous (under the skin) injections, beginning with twice weekly injections for the first 4 weeks, followed by once weekly doses for 48 weeks. Following the last treatment, a safety follow-up period of 24 weeks will be conducted.
Conditions
- Lupus Erythematosus, Systemic
Interventions
Atacicept 75 mgDrug
75 milligram (mg) atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
Atacicept 150 mgDrug
150 mg atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
Placebo ComparatorOther
Placebo matched to atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing a New Flare as Defined by British Isles Lupus Assessment Group (BILAG) Score A or BTime frame: From screening up to Week 52
Locations
113 sites in 29 countries. Site status is shown where the registry gives one.
Division of Clinical Immunology and Rheumatology - UAB
Birmingham, Alabama
Stanford University
Palo Alto, California
Research Site
San Diego, California
Inland Rheumatology Clinical Trials Inc
Upland, California
Research Site
Jacksonville, Florida
Research Site
Boise, Idaho
Brigham and Women's Hospital
Boston, Massachusetts
US Local Medical Information
Rockland, Massachusetts
Wayne State University
Detroit, Michigan
Justus J. Fiechtner, MD, MPH
Lansing, Michigan
SUNY Health Science Center at Brooklyn
Brooklyn, New York
Feinstein Institute for Medical Research
Manhasset, New York
Hospital for Special Surgey
New York, New York
Research Site
New York, New York
Research Site
Cincinnati, Ohio
University of Cincinnati Medical Center, Division of Immunology
Cincinnati, Ohio
Research Site
Temple, Texas
Virginia Mason Medical Center
Seattle, Washington
Research Site
Buenos Aires, Argentina
Research Site
Córdoba, Argentina
Research Site
Quilmes, Argentina
Research Site
San Juan, Argentina
Research Site
San Miguel de Tucumán, Argentina
Research Site
Cairns, Australia
Research Site
Clayton, Victoria, Australia
Research Site
Sunshine Coast, Queensland, Australia
Research Site
Woodville S.A., Australia
Research Site
Wein, Austria
Research Site
Sofia, Bulgaria
Research Site
Osijek, Croatia
Research Site
Rijeka, Croatia
Research Site
Split, Croatia
Research Site
Zagreb, Croatia
Research Site
Prague, Czechia
Research Site
Bordeaux Pessac, France
Research Site
Lille, France
Research Site
Montpelier Cedex, France
Research Site
Paris, France
Research Site
Strasbourg, France
Research Site
Toulouse, France
Showing 40 of 113 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.